Takeda Chooses Singapore For Asia Region Headquarters
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical, in a move to gain a bigger share of the drug market in Asia, has established regional headquarters in Singapore. Takeda is building on two subsidiaries in Singapore to expand its marketing efforts. Earlier this year, the company set up Takeda Pharmaceuticals Asia Private to market products in the Asian region and Takeda Clinical Research Singapore Private to develop pharmaceuticals. In addition, Takeda already had a small research center in a Singapore biotechnology hub. (Click here for more
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.